university website Publications by Year
  • Wealth
    • Erasmus Research Institute of Management (ERIM)
    • Erasmus School of Economics (ESE)
    • Rotterdam School of Management (RSM)
  • Health
    • Erasmus MC: University Medical Center Rotterdam
    • Erasmus School of Health Policy & Management (ESHPM)
  • Governance
    • Erasmus School of Law
    • Public Administration (FSS)
    • Netherlands Institute for Government (NIG)
    • Institute for Housing and Urban Development Studies (IHS)
  • Culture
    • Erasmus School of History, Culture and Communication (ESHCC)
    • Erasmus School of Social and Behavioural Sciences(ESSB)
    • Erasmus School of Philosophy (ESPhil)
    • International Institute of Social Studies (ISS)
  • Submissions
    • Submitting Publications
  • sign in
  • Department of Internal Medicine /
  • New England Journal of Medicine /
  • Article
  • Search

P.J. Trainer (Peter), M.T. Drake (Marcus), L. Katznelson (Laurence), P.U. Freda (Pamela), V. Herman-Bonert (Vivien), A-J. van der Lely (Aart-Jan), E.V. Dimaraki (Eleni), P.M. Stewart, K.E. Friend (Keith), M.L. Vance, et al. G.M. Besser (G. Michael) and J.A. Scarlett (John)

2000-04-20

Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant

Publication

Publication

New England Journal of Medicine , Volume 342 - Issue 16 p. 1171- 1177

Additional Metadata
Persistent URL doi.org/10.1056/NEJM200004203421604, hdl.handle.net/1765/55408
Journal New England Journal of Medicine
Organisation Department of Internal Medicine
Citation
APA Style
  • AAA Style
  • APA Style
  • Cell Style
  • Chicago Style
  • Harvard Style
  • IEEE Style
  • MLA Style
  • Nature Style
  • Vancouver Style
  • American-Institute-of-Physics Style
  • Council-of-Science-Editors Style
  • BibTex Format
  • Endnote Format
  • RIS Format
  • CSL Format
  • DOIs only Format
Trainer, P., Drake, M., Katznelson, L., Freda, P., Herman-Bonert, V., van der Lely, A.-J., … Scarlett, J. (2000). Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine, 342(16), 1171–1177. doi:10.1056/NEJM200004203421604
  • View at Publisher
  • View at Pubmed
  • View at Scopus
  • View at Web of Science


Sign in to view additional files

university website
  • About

    • Research Matters
    • Open Access
    • Privacy Statement
artudis website

Workflow

Workflow

Add Content


User Publication Person Organisation Collection
Close